This was the stock's second consecutive day of losses.

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by ...